Myelofibrosis (MF) can occur due to a wide variety of causes including malignant lymphoma. We report a case of splenic marginal zone lymphoma complicated by MF mimicking primary myelofibrosis (PMF). The JAK2, CALR and MPL mutations are detected in more than 90% of PMF cases, and when detected, the diagnosis of PMF is usually straight forward. Mutational analysis should be done in all cases of MF, and in triple-negative cases, an exhaustive investigation of other causes of MF should be carried out before a diagnosis of triple-negative PMF is rendered.
Introduction
Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoma typically presenting with splenomegaly and no lymphadenopathy. As in other types of malignant lymphoma, SMZL can also be complicated by myelofibrosis (MF), and we demonstrate that in such cases it can mimic primary myelofibrosis (PMF) and is a potential diagnostic pitfall. PMF is classified as one of the Ph-negative myeloproliferative neoplasms (MPNs). The JAK2, MPL and CALR mutations are highly specific for MPNs, and the diagnosis of PMF is straight forward once one of the mutations are detected. On top of this, only 8.7% of PMF cases are reported to be negative for JAK2, MPL and CALR mutations (triple-negative). MF can develop due to a wide variety of reactive causes, and an exhaustive investigation should be carried out before a diagnosis of triple-negative PMF is rendered.
Case Report
A 71-year-old-man presented with general malaise and weight loss from May 2014, and he was referred to our department in June 2014 with a presumptive diagnosis of PMF from a local hospital. On admission, the spleen was enlarged and palpable 12 cm below the left costal margin. White blood cell (WBC) count was 1.0 × 10 9 /L with 20.2% neutrophils, 45.2% lymphocytes, 20.2% monocytes, 10.6% eosinophils and 3.8% basophils. Hemoglobin (Hb) and platelet counts were 6.9 g/dL and 91 × 10 9 /L, respectively. Total bilirubin was slightly increased at 1.89 mg/dL, serum haptoglobin was below 10 mg/dL and direct coomb's test was positive, and thus complication with autoimmune hemolytic anemia (AIHA) was diagnosed. Peripheral blood flow cytometry was unremarkable with no light chain restriction. A whole body computed tomography (CT) scan revealed marked splenomegaly but no lymphadenopathy (Fig. 1a) . Bone marrow (BM) aspiration resulted in a dry tap, and BM biopsy revealed WHO-defined MF-2 with an increase of mature megakaryocytes (Fig. 1b) . JAK2, CALR, and MPL mutations were analyzed as previously described but were negative [1] , and the diagnosis was initially thought to be triple-negative PMF. However, because AIHA is often reported in conjunction with lymphoproliferative disorders, and soluble interleukin-2 receptor was found to be elevated at 4980 U/ml, we performed a CT-guided splenic needle biopsy to rule out lymphoma. Splenic biopsy revealed clustering of CD20-positive small lymphocytes which were negative for CD5, CD10, CD23, cyclinD1, SOX11, and LEF1 (Fig. 1c, d ). Fluorescence in situ hybridization (FISH) analysis performed on paraffin-embedded tissue sections were positive for the IgH (14q32) split signal, and negative for BCL2 (18q21), BCL6 (3q27), BCL10 (1p22), and MALT1 (18q21) split signals. Thus, a diagnosis of SMZL was made. Starting in mid-August 2014, rituximab was administered weekly at a dose of 375 mg/m 2 /day for 6 weeks resulting in a marked reduction of spleen size, improvement of pancytopenia, and he no longer needed red blood cell transfusions which were initially administered at approximately four units per week. The BM became aspirable, although BM biopsy still showed MF. Twelve additional bimonthly administrations of rituximab 375 mg/m 2 /day were carried out in the following two years. The spleen was not palpable as of January 2015 and the complete blood count normalized. Relapse of SMZL was seen in October 2017, and pancytopenia and splenomegaly recurred. However, readministration of rituximab again lead the patient to a second remission.
Discussion/Conclusion
SMZL mainly involves the spleen, BM, and peripheral blood, but peripheral lymphadenopathy is uncommon. Complication with MF has been reported in a variety of non-Hodgkin lymphomas such as diffuse large B-cell lymphoma, intravascular large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T cell lymphoma, NOS, but there is only 
